Amgen Inc. Available-for-sale Securities, Gross Realized Gains
Amgen Inc. (AMGN) reported Available-for-sale Securities, Gross Realized Gains of $17.00 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-04-25.
Discontinued › Income Statement › Other Income
us-gaap:AvailableForSaleSecuritiesGrossRealizedGains · last filed 2018-04-25
- Amgen Inc. available-for-sale securities, gross realized gains for the quarter ending 2018-03-31 was $17.00M, a 45.16% decline year-over-year.
- Amgen Inc. available-for-sale securities, gross realized gains for the quarter ending 2017-12-31 was $59.00M, a 156.52% increase year-over-year.
- Amgen Inc. available-for-sale securities, gross realized gains for the quarter ending 2017-09-30 was $38.00M, a 82.33% decline year-over-year.
- Amgen Inc. available-for-sale securities, gross realized gains for the quarter ending 2017-06-30 was $40.00M, a 29.03% increase year-over-year.
- Amgen Inc. available-for-sale securities, gross realized gains for fiscal 2017 was $172.00M, a 43.79% decline from fiscal 2016.
- Amgen Inc. available-for-sale securities, gross realized gains for fiscal 2016 was $306.00M, a 131.82% increase from fiscal 2015.
- Amgen Inc. available-for-sale securities, gross realized gains for fiscal 2015 was $132.00M, a 11.41% decline from fiscal 2014.
- Amgen Inc. available-for-sale securities, gross realized gains for fiscal 2014 was $149.00M.
| Period end | Available-for-sale Securities, Gross Realized Gains 3 month | Available-for-sale Securities, Gross Realized Gains 3 month as first filed | Available-for-sale Securities, Gross Realized Gains 6 month | Available-for-sale Securities, Gross Realized Gains 9 month | Available-for-sale Securities, Gross Realized Gains 12 month |
|---|---|---|---|---|---|
| 2018-03-31 | $17.00M 10-Q · filed 2018-04-25 | $76.00M derived: sum of 2 quarters · filed 2018-04-25 | $114.00M derived: sum of 3 quarters · filed 2018-04-25 | $154.00M derived: sum of 4 quarters · filed 2018-04-25 | |
| 2017-12-31 | $59.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $97.00M derived: sum of 2 quarters · filed 2018-02-13 | $137.00M derived: sum of 3 quarters · filed 2018-02-13 | $172.00M 10-K · filed 2018-02-13 | |
| 2017-09-30 | $38.00M 10-Q · filed 2017-10-26 | $78.00M derived: sum of 2 quarters · filed 2017-10-26 | $113.00M 10-Q · filed 2017-10-26 | $132.00M derived: sum of 4 quarters · filed 2018-04-25 | |
| 2017-06-30 | $40.00M 10-Q · filed 2017-07-26 | $75.00M 10-Q · filed 2017-07-26 | $94.00M derived: sum of 3 quarters · filed 2018-04-25 | $309.00M derived: sum of 4 quarters · filed 2018-04-25 | |
| 2017-03-31 | $31.00M 10-Q · filed 2018-04-25 | $35.00M 10-Q · filed 2017-04-27 | $54.00M derived: sum of 2 quarters · filed 2018-04-25 | $269.00M derived: sum of 3 quarters · filed 2018-04-25 | $300.00M derived: sum of 4 quarters · filed 2018-04-25 |
| 2016-12-31 | $23.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $238.00M derived: sum of 2 quarters · filed 2018-02-13 | $269.00M derived: sum of 3 quarters · filed 2018-02-13 | $306.00M 10-K · filed 2018-02-13 | |
| 2016-09-30 | $215.00M 10-Q · filed 2017-10-26 | $246.00M derived: sum of 2 quarters · filed 2017-10-26 | $283.00M 10-Q · filed 2017-10-26 | $342.00M derived: sum of 4 quarters · filed 2018-02-13 | |
| 2016-06-30 | $31.00M 10-Q · filed 2017-07-26 | $68.00M 10-Q · filed 2017-07-26 | $127.00M derived: sum of 3 quarters · filed 2018-02-13 | $146.00M derived: sum of 4 quarters · filed 2018-02-13 | |
| 2016-03-31 | $37.00M 10-Q · filed 2017-04-27 | $96.00M derived: sum of 2 quarters · filed 2018-02-13 | $115.00M derived: sum of 3 quarters · filed 2018-02-13 | $133.00M derived: sum of 4 quarters · filed 2018-02-13 | |
| 2015-12-31 | $59.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $78.00M derived: sum of 2 quarters · filed 2018-02-13 | $96.00M derived: sum of 3 quarters · filed 2018-02-13 | $132.00M 10-K · filed 2018-02-13 | |
| 2015-09-30 | $19.00M 10-Q · filed 2016-10-28 | $37.00M derived: sum of 2 quarters · filed 2016-10-28 | $73.00M 10-Q · filed 2016-10-28 | $120.00M derived: sum of 4 quarters · filed 2017-02-14 | |
| 2015-06-30 | $18.00M 10-Q · filed 2016-07-29 | $54.00M 10-Q · filed 2016-07-29 | $101.00M derived: sum of 3 quarters · filed 2017-02-14 | $118.00M derived: sum of 4 quarters · filed 2017-02-14 | |
| 2015-03-31 | $36.00M 10-Q · filed 2016-05-02 | $83.00M derived: sum of 2 quarters · filed 2017-02-14 | $100.00M derived: sum of 3 quarters · filed 2017-02-14 | $157.00M derived: sum of 4 quarters · filed 2017-02-14 | |
| 2014-12-31 | $47.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-14 | $64.00M derived: sum of 2 quarters · filed 2017-02-14 | $121.00M derived: sum of 3 quarters · filed 2017-02-14 | $149.00M 10-K · filed 2017-02-14 | |
| 2014-09-30 | $17.00M 10-Q · filed 2015-11-02 | $74.00M derived: sum of 2 quarters · filed 2015-11-02 | $102.00M 10-Q · filed 2015-11-02 | $118.00M derived: sum of 4 quarters · filed 2016-10-31 | |
| 2014-06-30 | $57.00M 10-Q · filed 2015-08-05 | $85.00M 10-Q · filed 2015-08-05 | $101.00M derived: sum of 3 quarters · filed 2016-10-31 | $125.00M derived: sum of 4 quarters · filed 2016-10-31 | |
| 2014-03-31 | $28.00M 10-Q · filed 2015-04-27 | $44.00M derived: sum of 2 quarters · filed 2016-10-31 | $68.00M derived: sum of 3 quarters · filed 2016-10-31 | $101.00M derived: sum of 4 quarters · filed 2016-10-31 | |
| 2013-12-31 | $16.00M derived: 8-K 12 month − 10-Q 9 month · filed 2016-10-31 | $40.00M derived: sum of 2 quarters · filed 2016-10-31 | $73.00M derived: sum of 3 quarters · filed 2016-10-31 | $158.00M 8-K · filed 2016-10-31 | |
| 2013-09-30 | $24.00M 10-Q · filed 2014-10-29 | $57.00M derived: sum of 2 quarters · filed 2014-10-29 | $142.00M 10-Q · filed 2014-10-29 | $181.00M derived: sum of 4 quarters · filed 2015-02-19 | |
| 2013-06-30 | $33.00M 10-Q · filed 2014-08-05 | $118.00M 10-Q · filed 2014-08-05 | $157.00M derived: sum of 3 quarters · filed 2015-02-19 | $188.00M derived: sum of 4 quarters · filed 2015-02-19 | |
| 2013-03-31 | $85.00M 10-Q · filed 2014-04-30 | $124.00M derived: sum of 2 quarters · filed 2015-02-19 | $155.00M derived: sum of 3 quarters · filed 2015-02-19 | $204.00M derived: sum of 4 quarters · filed 2015-02-19 | |
| 2012-12-31 | $39.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-19 | $70.00M derived: sum of 2 quarters · filed 2015-02-19 | $119.00M derived: sum of 3 quarters · filed 2015-02-19 | $186.00M 10-K · filed 2015-02-19 | |
| 2012-09-30 | $31.00M 10-Q · filed 2013-10-29 | $80.00M derived: sum of 2 quarters · filed 2013-10-29 | $147.00M 10-Q · filed 2013-10-29 | $169.00M derived: sum of 4 quarters · filed 2014-02-24 | |
| 2012-06-30 | $49.00M 10-Q · filed 2013-08-06 | $116.00M 10-Q · filed 2013-08-06 | $138.00M derived: sum of 3 quarters · filed 2014-02-24 | $170.00M derived: sum of 4 quarters · filed 2014-02-24 | |
| 2012-03-31 | $67.00M 10-Q · filed 2013-05-03 | $89.00M derived: sum of 2 quarters · filed 2014-02-24 | $121.00M derived: sum of 3 quarters · filed 2014-02-24 | $169.00M derived: sum of 4 quarters · filed 2014-02-24 | |
| 2011-12-31 | $22.00M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-24 | $54.00M derived: sum of 2 quarters · filed 2014-02-24 | $102.00M derived: sum of 3 quarters · filed 2014-02-24 | $191.00M 10-K · filed 2014-02-24 | |
| 2011-09-30 | $32.00M 10-Q · filed 2012-11-06 | $80.00M derived: sum of 2 quarters · filed 2012-11-06 | $169.00M 10-Q · filed 2012-11-06 | $192.00M derived: sum of 4 quarters · filed 2013-02-27 | |
| 2011-06-30 | $48.00M 10-Q · filed 2012-08-08 | $137.00M 10-Q · filed 2012-08-08 | $160.00M derived: sum of 3 quarters · filed 2013-02-27 | $194.00M derived: sum of 4 quarters · filed 2013-02-27 | |
| 2011-03-31 | $89.00M 10-Q · filed 2012-05-08 | $112.00M derived: sum of 2 quarters · filed 2013-02-27 | $146.00M derived: sum of 3 quarters · filed 2013-02-27 | $182.00M derived: sum of 4 quarters · filed 2013-02-27 | |
| 2010-12-31 | $23.00M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-27 | $57.00M derived: sum of 2 quarters · filed 2013-02-27 | $93.00M derived: sum of 3 quarters · filed 2013-02-27 | $115.00M 10-K · filed 2013-02-27 | |
| 2010-09-30 | $34.00M 10-Q · filed 2011-11-04 | $70.00M derived: sum of 2 quarters · filed 2011-11-04 | $92.00M 10-Q · filed 2011-11-04 | $118.00M derived: sum of 4 quarters · filed 2012-02-29 | |
| 2010-06-30 | $36.00M 10-Q · filed 2011-08-08 | $58.00M 10-Q · filed 2011-08-08 | $84.00M derived: sum of 3 quarters · filed 2012-02-29 | $101.00M derived: sum of 4 quarters · filed 2012-02-29 | |
| 2010-03-31 | $21.00M 10-Q · filed 2011-05-10 | $48.00M derived: sum of 2 quarters · filed 2012-02-29 | $65.00M derived: sum of 3 quarters · filed 2012-02-29 | $91.00M derived: sum of 4 quarters · filed 2012-02-29 | |
| 2009-12-31 | $27.00M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | $44.00M derived: sum of 2 quarters · filed 2012-02-29 | $70.00M derived: sum of 3 quarters · filed 2012-02-29 | $104.00M 10-K · filed 2012-02-29 | |
| 2009-09-30 | $17.00M 10-Q · filed 2010-11-08 | $43.00M derived: sum of 2 quarters · filed 2010-11-08 | $77.00M 10-Q · filed 2010-11-08 | ||
| 2009-06-30 | $26.00M 10-Q · filed 2010-08-09 | $60.00M 10-Q · filed 2010-08-09 | |||
| 2008-12-31 | $124.00M 10-K · filed 2011-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |